株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のリキッドバイオプシー市場:用途、検体(血液、尿)、バイオマーカー(CTC、ctDNA、エキソソーム)、技術(NGS、PCR)、地域別 2018年~2030年

Liquid Biopsy Market Size, Share & Trends Analysis Report By Application, By Sample Type (Blood, Urine) By Biomarker Type (CTC, ctDNA, Exosomes), By Technology (NGS, PCR), By Region, And Segment Forecasts, 2018 - 2030

発行 Grand View Research, Inc. 商品コード 374558
出版日 ページ情報 英文 150 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
世界のリキッドバイオプシー市場:用途、検体(血液、尿)、バイオマーカー(CTC、ctDNA、エキソソーム)、技術(NGS、PCR)、地域別 2018年~2030年 Liquid Biopsy Market Size, Share & Trends Analysis Report By Application, By Sample Type (Blood, Urine) By Biomarker Type (CTC, ctDNA, Exosomes), By Technology (NGS, PCR), By Region, And Segment Forecasts, 2018 - 2030
出版日: 2018年05月23日 ページ情報: 英文 150 Pages
概要

世界のリキッドバイオプシー市場は、2018年から2030年にかけて13.4%のCAGRで推移し、2030年までに59億6,000万米ドル規模に成長することが予測されています。がん診断において標準とされている従来の組織生検は、侵襲的な検査で合併症が大きな懸念事項とされています。一方、リキッドバイオプシーは高効率で低侵襲であるために患者負担が少なく済みます。リキッドバイオプシーによるがんの早期発見技術が、当市場の成長を促進する見通しです。

当レポートでは、世界のリキッドバイオプシー市場を調査し、市場の概要、市場動向、用途・検体・バイオマーカー・技術・地域別の市場規模の推移と予測、成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 調査方法と範囲

第2章 エグゼクティブサマリー

  • 市場のスナップショット

第3章 市場変数・動向・範囲

  • 市場区分
  • 市場規模と成長の見通し
  • パイプライン分析
  • SWOT分析
  • ファイブフォース分析

第4章 リキッドバイオプシー市場:用途別

  • 市場動向の分析:用途別
  • 転移性乳がん(MBS)
  • その他の転移性がん
  • 分子ヘルスモニタリング

第5章 リキッドバイオプシー市場:検体別

  • 市場動向の分析:検体別
  • 血液
  • 尿
  • 唾液

第6章 リキッドバイオプシー市場:バイオマーカー別

  • 市場動向の分析:バイオマーカー別
  • 血中循環腫瘍DNA(ctDNA)
  • 血中循環腫瘍細胞(CTC)
  • エキソソーム

第7章 リキッドバイオプシー市場:技術別

  • 市場動向の分析:技術別
  • 次世代シーケンサー(NGS)を用いたマルチ遺伝子並列解析
  • ポリメラーゼ連鎖反応(PCR)マイクロアレイを用いた単一遺伝子解析

第8章 リキッドバイオプシー市場:地域別

  • 市場シェア:地域別(実績値・予測値)
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 戦略の枠組み
  • 参入企業の分類
  • 企業プロファイル
    • Vermillion, Inc.
    • Genomic Health, Inc.
    • Foundation Medicine, Inc.
    • Biocept, Inc.
    • Myriad Genetics, Inc.
    • OncoCyte Corporation
    • Veracyte, Inc, Inc.
    • Guardant Health, Inc.
    • NeoGenomics Laboratories, Inc.
    • Personal Genome Diagnostics, Inc.
    • QIAGEN
    • RainDance Technologies, Inc.
    • Adaptive Biotechnologies.
    • Trovagene Inc.
    • Cynvenio Biosystems, Inc.
図表

List of Tables

  • Table 1. North America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 2. North America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 3. North America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 4. North America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 5. U.S. liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 6. U.S. liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 7. U.S. liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 8. U.S. liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 9. Canada liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 10. Canada liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 11. Canada liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 12. Canada liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 13. Europe liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 14. Europe liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 15. Europe liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 16. Europe liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 17. Germany liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 18. Germany liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 19. Germany liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 20. Germany liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 21. U.K. liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 22. U.K. liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 23. U.K. liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 24. U.K. liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 25. Asia Pacific liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 26. Asia Pacific liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 27. Asia Pacific liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 28. Asia Pacific liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 29. Japan liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 30. Japan liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 31. Japan liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 32. Japan liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 33. China liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 34. China liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 35. China liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 36. China liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 37. Latin America liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 38. Latin America liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 39. Latin America liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 40. Latin America liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 41. Brazil liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 42. Brazil liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 43. Brazil liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 44. Brazil liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 45. MEA liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 46. MEA liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 47. MEA liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 48. MEA liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)
  • Table 49. South Africa liquid biopsy market estimates & forecasts, by application, 2013 - 2030 (USD Million)
  • Table 50. South Africa liquid biopsy market estimates & forecasts, by sample type, 2013 - 2030 (USD Million)
  • Table 51. South Africa liquid biopsy market estimates & forecasts, by biomarker, 2013 - 2030 (USD Million)
  • Table 52. South Africa liquid biopsy market estimates & forecasts, by technology, 2013 - 2030 (USD Million)

List of Figures

  • Fig. 1. Market research process
  • Fig. 2. Information procurement
  • Fig. 3. Primary research pattern
  • Fig. 4. Market research approaches
  • Fig. 5. Value chain based sizing & forecasting
  • Fig. 6. Market summary
  • Fig. 7. Market trends & outlook
  • Fig. 8. Market segmentation & scope
  • Fig. 9. Market driver relevance analysis (current & future impact)
  • Fig. 10. Market restraint relevance analysis (current & future impact)
  • Fig. 11. Penetration & growth prospect mapping, 2015 - 2030
  • Fig. 12. SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 13. Porter's Five Forces Analysis
  • Fig. 14. Liquid biopsy market: Application outlook key takeaways
  • Fig. 15. Liquid biopsy market: Application movement analysis
  • Fig. 16. Global therapy selection for MBS market, 2013 - 2030 (USD Million)
  • Fig. 17. Global therapy selection for other metastatic cancer market, 2013 - 2030 (USD Million)
  • Fig. 18. Global molecular monitoring market, 2013 - 2030 (USD Million)
  • Fig. 19. Liquid biopsy market: Sample type outlook key takeaways
  • Fig. 20. Liquid biopsy market: Sample type movement analysis
  • Fig. 21. Global blood sample based market, 2013 - 2030 (USD Million)
  • Fig. 22. Global urine sample based market, 2013 - 2030 (USD Million)
  • Fig. 23. Global other bio fluid (tissue fluid and saliva) sample based market, 2013 - 2030 (USD Million)
  • Fig. 24. Liquid biopsy market: biomarker outlook key takeaways
  • Fig. 25. Liquid biopsy market: biomarker movement analysis
  • Fig. 26. Global CTC based liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 27. Global ctDNA based liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 28. Global exosomes based liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 29. Liquid biopsy market: Technology outlook key takeaways
  • Fig. 30. Liquid biopsy market: Technology movement analysis
  • Fig. 31. Global multi-gene analysis using NGS market, 2013 - 2030 (USD Million)
  • Fig. 32. Global single gene analysis using PCR microarrays market, 2013 - 2030 (USD Million)
  • Fig. 33. Regional market place: Key takeaway
  • Fig. 34. Liquid biopsy market regional outlook, 2015 & 2024
  • Fig. 35. North America liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 36. U.S. liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 37. Canada liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 38. Europe liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 39. Germany liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 40. U.K. liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 41. Asia Pacific liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 42. Japan liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 43. China liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 44. Latin America liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 45. Brazil liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 46. MEA liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 47. South Africa liquid biopsy market, 2013 - 2030 (USD Million)
  • Fig. 48. Strategy framework
  • Fig. 49. Participant categorization
目次
Product Code: GVR-1-68038-105-4

The global liquid biopsy market size is expected to reach USD 5.96 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.

While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.

Further key findings from the report suggest:

Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period

Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years

Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market

Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market

Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests

Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region Wise Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 Region based segment share calculation
  • 1.3 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Liquid Biopsy Market Variables, Trends& Scope

  • 3.1 Market Segmentation& Scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 High cost addition to traditional biopsies due to complications & adverse events
      • 3.1.1.2 Highly invasive nature of traditional biopsies
      • 3.1.1.3 Inadequacy of collected samples for solid biopsy
      • 3.1.1.4 Assessment of intra-tumor heterogeneity
      • 3.1.1.5 Ability of liquid biopsies to provide insights into metastatic cancers
      • 3.1.1.6 Increasing prevalence of cancer
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Unclear reimbursement related to costs of liquid biopsies
      • 3.1.2.2 Lack of knowledge of physicians about genomic analysis & liquid biopsies
      • 3.1.2.3 Challenges associated with NGS implementation
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Liquid Biopsy Pipeline Analysis
    • 3.3.1 Liquid Biopsy Pipeline Analysis
  • 3.4 Liquid Biopsy - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.5 Industry Analysis - Porter's

Chapter 4 Liquid Biopsy Application Estimates & Trend Analysis

  • 4.1 Liquid Biopsy Market: Application Movement Analysis
  • 4.2 Therapy Selection for Metastatic Breast Cancer (MBS)
    • 4.2.1 Global therapy selection for MBS market, 2013 - 2030 (USD Million)
  • 4.3 Therapy Selection for Other Metastatic Cancer
    • 4.3.1 Global therapy selection for other metastatic cancer market, 2013 - 2030 (USD Million)
  • 4.4 Molecular Health Monitoring
    • 4.4.1 Global molecular health monitoring market, 2013 - 2030 (USD Million)

Chapter 5 Liquid Biopsy Sample Type Estimates & Trend Analysis

  • 5.1 Liquid Biopsy Market: Sample Type Movement Analysis
  • 5.2 Blood Sampling LB
    • 5.2.1 Global blood sampling LB market, 2013 - 2030 (USD Million)
  • 5.3 Urine Sampling LB
    • 5.3.1 Global urine sampling LB market, 2013 - 2030 (USD Million)
  • 5.4 Saliva & other tissue fluids sampling LB
    • 5.4.1 Global saliva & other tissue fluids samplingLB market, 2013 - 2030 (USD Million)

Chapter 6 Liquid Biopsy Biomarker Type Estimates & Trend Analysis

  • 6.1 Liquid Biopsy Market: Biomarker Types Movement Analysis
  • 6.2 Circulating Tumor DNA (ctDNA)
    • 6.2.1 Global circulating tumor DNA (ctDNA) market, 2013 - 2030 (USD Million)
  • 6.3 Circulating Tumor Cells (CTC)
    • 6.3.1 Global circulating tumor cells (CTC)market, 2013 - 2030 (USD Million)
  • 6.4 Exosomes (Macrovesicles with Protein, RNA, DNA)
    • 6.4.1 Global exosomes (macrovesicles with protein, RNA, DNA) market, 2013 - 2030 (USD Million)

Chapter 7 Liquid Biopsy Technology Estimates & Trend Analysis

  • 7.1 Liquid Biopsy Market: Technology Movement Analysis
  • 7.2 Multi-gene-parallel Analysis using NGS
    • 7.2.1 Global multi-gene parallel analysis using NGS market, 2013 - 2030 (USD Million)
  • 7.3 Single Gene Analysis using PCR Microarrays
    • 7.3.1 Global single gene analysis using PCR microarrays market, 2013 - 2030 (USD Million)

Chapter 8 Liquid Biopsy: Regional Estimates & Trend Analysis, by Application, Sample-Type, Biomarker & Technology

  • 8.1 Liquid biopsy market share by region, 2016 & 2030
  • 8.2 North America
    • 8.2.1 North America liquid biopsy market, 2013 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.2.2.2 U.S. liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.2.2.3 U.S. liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.2.2.4 U.S. liquid biopsy market, by technology, 2013 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Canada liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.2.3.2 Canada liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.2.3.3 Canada liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.2.3.4 Canada liquid biopsy market, by technology, 2013 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe liquid biopsy market, 2013 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Germany liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.3.2.2 Germany liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.3.2.3 Germany liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.3.2.4 Germany liquid biopsy market, by technology, 2013 - 2030 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 U.K. liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.3.3.2 U.K. liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.3.3.3 U.K. liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.3.3.4 U.K. liquid biopsy market, by technology, 2013 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific liquid biopsy market, 2013 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Japan liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.4.2.2 Japan liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.4.2.3 Japan liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.4.2.4 Japan liquid biopsy market, by technology, 2013 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 China liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.4.3.2 China liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.4.3.3 China liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.4.3.4 China liquid biopsy market, by technology, 2013 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America liquid biopsy market, 2013 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.5.2.2 Brazil liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.5.2.3 Brazil liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.5.2.4 Brazil liquid biopsy market, by technology, 2013 - 2030 (USD Million)
  • 8.6 Middle East & Africa (MEA)
    • 8.6.1 Middle East & Africa liquid biopsy market, 2013 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa liquid biopsy market, by application, 2013 - 2030 (USD Million)
      • 8.6.2.2 South Africa liquid biopsy market, by sample type, 2013 - 2030 (USD Million)
      • 8.6.2.3 South Africa liquid biopsy market, by biomarker, 2013 - 2030 (USD Million)
      • 8.6.2.4 South Africa liquid biopsy market, by technology, 2013 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy framework
  • 9.2 Market participation categorization
  • 9.3 Company Profiles
    • 9.3.1 Vermillion, Inc.
      • 9.3.1.1 Company overview
      • 9.3.1.2 Financial performance
      • 9.3.1.3 Product benchmarking
      • 9.3.1.4 Strategic initiatives
    • 9.3.2 Genomic Health, Inc.
      • 9.3.2.1 Company overview
      • 9.3.2.2 Financial performance
      • 9.3.2.3 Product benchmarking
      • 9.3.2.4 Strategic initiatives
    • 9.3.3 Foundation Medicine, Inc.
      • 9.3.3.1 Company overview
      • 9.3.3.2 Financial Performance
      • 9.3.3.3 Product benchmarking
      • 9.3.3.4 Strategic initiatives
    • 9.3.4 Biocept, Inc.
      • 9.3.4.1 Company overview
      • 9.3.4.2 Financial performance
      • 9.3.4.3 Product benchmarking
      • 9.3.4.4 Strategic initiatives
    • 9.3.5 Myriad Genetics, Inc.
      • 9.3.5.1 Company overview
      • 9.3.5.2 Financial performance
      • 9.3.5.3 Product benchmarking
      • 9.3.5.4 Strategic initiatives
    • 9.3.6 OncoCyte Corporation
      • 9.3.6.1 Company overview
      • 9.3.6.2 Financial performance
      • 9.3.6.3 Product benchmarking
      • 9.3.6.4 Strategic initiatives
    • 9.3.7 Veracyte, Inc, Inc.
      • 9.3.7.1 Company overview
      • 9.3.7.2 Financial performance
      • 9.3.7.3 Product benchmarking
      • 9.3.7.4 Strategic initiatives
    • 9.3.8 Guardant Health, Inc.
      • 9.3.8.1 Company overview
      • 9.3.8.2 Financial performance
      • 9.3.8.3 Product benchmarking
      • 9.3.8.4 Strategic initiatives
    • 9.3.9 NeoGenomics Laboratories, Inc.
      • 9.3.9.1 Company overview
      • 9.3.9.2 Financial performance
      • 9.3.9.3 Product benchmarking
      • 9.3.9.4 Strategic initiatives
    • 9.3.10 Personal Genome Diagnostics, Inc.
      • 9.3.10.1 Company overview
      • 9.3.10.2 Financial performance
      • 9.3.10.3 Product benchmarking
      • 9.3.10.4 Strategic initiatives
    • 9.3.11 QIAGEN
      • 9.3.11.1 Company overview
      • 9.3.11.2 Financial performance
      • 9.3.11.3 Product benchmarking
      • 9.3.11.4 Strategic initiatives
    • 9.3.12 RainDance Technologies, Inc.
      • 9.3.12.1 Company overview
      • 9.3.12.2 Financial performance
      • 9.3.12.3 Product benchmarking
      • 9.3.12.4 Strategic initiatives
    • 9.3.13 Adaptive Biotechnologies.
      • 9.3.13.1 Company overview
      • 9.3.13.2 Financial performance
      • 9.3.13.3 Product benchmarking
      • 9.3.13.4 Strategic initiatives
    • 9.3.14 Trovagene Inc.
      • 9.3.14.1 Company overview
      • 9.3.14.2 Financial performance
      • 9.3.14.3 Product benchmarking
      • 9.3.14.4 Strategic initiatives
    • 9.3.15 Cynvenio Biosystems, Inc.
      • 9.3.15.1 Company overview
      • 9.3.15.2 Financial performance
      • 9.3.15.3 Product benchmarking
      • 9.3.15.4 Strategic initiatives